The CD180 CART cell therapy is being developed by the Institute of Hematology & Blood Diseases Hospital in China, focusing on relapsed or refractory acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia/lymphoma (B-ALL/LBL). The trial's single-arm design and dose escalation strategy may provide insights into the safety and efficacy of this novel therapy. Given the high unmet need in treating relapsed/refractory hematologic malignancies, successful outcomes could position this therapy favorably in a competitive landscape dominated by existing CAR-T therapies. The market for CAR-T therapies is expanding, with significant potential for growth, particularly in the Asian markets where this trial is being conducted. Diligence should focus on the trial's recruitment progress and the regulatory landscape in China, as well as potential partnerships for commercialization.